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Abstract
Resistance of parasitic nematodes to anthelmintic drugs is a gro-
wing problem in human and veterinary medicine. The molecular 
mechanisms by which nematodes become resistant are different, 
but certainly one of the possible processes involves changing 
the drug binding site on the specific receptor. The significance of 
changes in individual subtypes of nicotinic acetylcholine receptors 
(nAChRs) for the development of resistance has not been clarified in 
detail. This study investigates the interaction of antinematodal drugs, 
agonist of different types of nAChRs and carvacrol with gamma 
aminobutyric acid (GABA) on the contractions of parasitic nematode 
A. suum. In our study, GABA (3 μ M) produced significant increase of 
contractile EC50 value for pyrantel, and nonsignificant for bephenium 
and morantel, from 8.44 to 28.11 nM, 0.62 to 0.96 µM, and 3.72 to 
5.69 nM, respectively. On the other hand, the maximal contractile 
effect (Rmax) did not change in the presence of GABA. However, when 
A. summ muscle flaps were incubated with GABA 3 μ M and carvacrol 
100 μ M, the EC50 value of pyrantel, bephenium, and morantel was 
increased significantly to 44.62 nM, 1.40 μ M, and nonsignificantly to 
7.94 nM, respectively. Furthermore, Rmax decreased by 70, 60, and 
65%. Presented results indicate that the combined use of GABA 
receptor agonists and nicotinic receptor antagonists can effectively 
inhibit the neuromuscular system of nematodes, even when one of 
the nicotinic receptor subtypes is dysfunctional, due to the potential 
development of resistance.
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A number of excitatory and inhibitory neurotransmitters 
are involved in the regulation of somatic muscle 
contractions in nematodes. It is well known that 
excitatory and inhibitory neurons, whose coordinated 
activity ensures sinusoidal movement have an 
equivalent role in nematode locomotion. The excitation 
of somatic muscles is provided by acetylcholine 
(ACh), which leads to contraction. Cholinergic 
transmission occurs both between neurons and at 
the neuromuscular junction. Furthermore, the con-
traction of the ventral wall causes the dorsal wall to 
relax on the other side of the body. The relaxation 
of the somatic muscles takes place through GABA, 
and in this way the two neurotransmitters coordinate 
the movement of the nematode. Acetylcholine (ACh) 
is a neurotransmitter in the excitatory synapses, 
while GABA is the neurotransmitter in the inhibitory 
synapses between interneurons and motor neurons. 
These interneurons could be related evolutionarily 
to mammalian Renshaw cells, and are potentially 
a very attractive drug target (Trailovic and Varagic, 
2007).
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The most commonly used antinematodal 
drugs in human and veterinary medicine are cho-
linergic agonists: imidazothiazole (levamisole), tetra-
hydropyrimidines (pyrantel, morantel and oxantel), 
quaternary/tertiary amines (bephenium and triben-
dimidine), pyridines (methyridine), and amino-
acetonitrile derivatives (AADs; monepantel). This 
group of drugs produces spastic paralysis of the 
nematode by selectively gating acetylcholine receptor 
ion-channels at the synapses of motor neurons and 
interneurons, or at somatic muscle cells. The result of 
opening of the sodium ion channel is depolarization, 
followed by a contraction (Holden-Dye et al., 1989). 
Pharmacologically, the nematode muscle nicotinic 
acetylcholine receptors (nAChRs) have similarities 
to the vertebrate neuronal receptor, because it is 
relatively insensitive to block by bungarotoxin (Tornøe 
et al., 1995). Unlike the vertebrates, there is more 
than one type of nAChR found in the musculature of 
adult nematodes. In Ascaris suum, there are at least 
three types of nAChR located on the muscle, with 
distinguishable pharmacological and single-channel 
properties. Each of the three subtypes was named 
based on its preferred agonist, N (prefers nicotine 
and oxantel), L (prefers levamisole and pyrantel), and 
B (prefers bephenium) (Martin et al., 2004; Robertson 
et al., 2002).
Another large group of antinematodal drugs are 
avermectins. Avermectins interact with the gamma 
aminobutyric acid (GABA) receptor in somatic 
muscle, and the glutamate-gated chloride channel, 
which exists only in the pharynx of nematodes. This 
interaction leads to increased permeability of the 
postsynaptic membrane to chloride ions, causing 
hyperpolarization of the membrane and muscle 
relaxation, or atonic paralysis and death of parasites 
(Holden-Dye and Walker, 2005-2018; Puttachary et al., 
2013; Wolstenholme, 2011).
In addition to receptors on nerve-muscle synapses, 
it was proved that functional GABA and nicotinic 
receptors exist extrasynaptically in the bag region 
of Ascaris muscle cells (Martin, 1982). These are the 
reasons why a large number of antinematodal drugs 
act on the nicotinic or GABA receptor and thus disrupt 
the locomotion of the parasite, which ultimately leads 
to death.
Carvacrol is a phenolic monoterpenoid, present 
as a secondary metabolite in many plant essential 
oils, such as thyme oil and oregano oil. Evidence 
of antinematodal effects of carvacrol has been 
published both in vivo and in vitro experiments. Our 
previous studies have shown that carvacrol is most 
likely a non-competitive antagonist of nAChRs in 
parasitic nematodes (Marjanović et al., 2020; Trailović 
et al., 2015). Furthermore, Lei et al. (2010) showed that 
carvacrol and thymol at concentrations of 330 μ M 
caused an A. suum mortality rate of 80% (in vitro test 
during 24 hr).
We considered it important to examine the 
effect of antinematodal drugs, agonists of different 
types of nAChRs and carvacrol with GABA on the 
contractions of the parasitic nematode A. suum. This 
study could indicate the possibility of using two or 
more antinematodal drugs with different mechanisms 




Adult females of Ascaris suum were collected at 
the Ambar slaughterhouse in Surčin, Serbia and 
maintained in Locker solution (mM): NaCl 155, KCl 5, 
CaCl2 2, NaHCO3 1.5, and glucose 5, at a temperature 
of 32°C. The locker solution was changed twice a day. 
After collection, the worms were used for contractions 
assay for the next four days. Ascaris muscle flaps for 
contractions were prepared as previously described 
(Trailović et al., 2016). Each flap (always the same 
length of 1 cm) was monitored isometrically by 
attaching a force transducer in an experimental 
bath maintained at 37°C, containing 20 ml Ascaris 
Perienteric Fluid Ringer/APF-Ringer (mM): NaCl, 23; 
Na-acetate, 110; KCl, 24; CaCl2, 6; MgCl, 5; glucose, 
11; HEPES, 5; pH 7.6, and bubbled with room air. 
After dissection, the preparations were allowed to 
equilibrate for 15 min under the initial tension of 0.5 g. 
Different concentrations of pyrantel, morantel, and 
bephenium were then added to the preparation, 
and the maximum contraction was observed before 
the washing and subsequent application of the next 
concentration of the drug. The responses for each 
concentration were expressed in grams (g), produced 
by each individual flap preparation. The effects of 
GABA (3 μ M), and GABA + carvacrol 100 μ M on control 
dose-response plots were determined. Contractions 
were monitored on a PC computer, using a BioSmart 
interface, and eLAB 44 software (ElUnit, Belgrade). 
Sigmoidal concentration-response curves for each 
agonist in the absence or presence of antagonist 
were described by the Hill equation.
Drugs
Carvacrol, morantel, pyrantel, bephenium, and GABA 
were obtained from Sigma-Aldrich Co (St Louis, MO, 
USA). Morantel, pyrantel, bephenium, and GABA 
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were dissolved in the APF-Ringer, while carvacrol 
was dissolved in ethanol, with the final concentration 
of ethanol in the APF-Ringer of 0.1%v/v. When tested, 
0.1% of ethanol did not alter the resting activity of 
preparations and did not alter the drug responses.
Data analysis
In the studies presented here, sigmoid concentration 
dose–responses were described by the equation: 
% response = 1/1 + [EC50/Xa]nH, where the median 
effective concentration (EC50) is the concentration 
of the agonist (Xa) producing 50% of the maximum 
response and nH is the Hill coefficient (slope). Prism 
6.0 (GraphPad Software, San Diego, California, 
USA) was used to estimate the constants EC50 and 
nH, by non-linear regression for each preparation. 
We determined mean contraction responses to 
each concentration of ACh (control dose-response: 
CR[Ach]) and mean responses to each of the 
concentrations of ACh in the presence of GABA. 
One-way analysis of variance (ANOVA) was applied 
for the analysis of the differences between the EC50 
value and the Rmax (maximal effect). Differences were 
considered significant when the p value was < 0.05. 
The statistical analysis was done using Graphpad 
Prism software, while all values are expressed as 
mean ± standard error (S.E.).
Results
In our study, pyrantel caused concentration-dependent 
contractions of neuromuscular preparation of A. suum 
(Fig. 1A). After incubation with 3 μ M of GABA, the 
EC50 of pyrantel increased significantly from 8.44 to 
28.22 nM (Table 1). However, when the muscle flaps 
were incubated with GABA 3 μ M and carvacrol 100 μ M 
at the same time, the EC50 of pyrantel reached as 
much as 44 nM, which is significantly higher than the 
control value and the EC50 of pyrantel after incubation 
with GABA 3 μ M (Table 1). Part of this inhibitory effect 
is reversible, as after washing, the EC50 value of 
pyrantel returned to the level observed in the presence 
of GABA 3 μ M, but did not reach the initial control 
level. On the other hand, the value of the maximum 
contractile effect (Rmax) of pyrantel has not changed 
in the presence of GABA 3 μ M, but decreased 
significantly after incubation with combination of GABA 
and carvacrol (Table 2 and Fig. 1B).
The control value of the bephenium EC50 was 
0.62 μ M and it increased nonsignificantly to 0.96 μ M 
in the presence of GABA 3 μ M (Table 1). A representa-
tive recording of contractions caused by bephenium 
and the sigmoid concentration dose–responses plot 
are shown in Figure 2A, B. Furthermore, the EC50 
value of bephenium reached a level of 1.44 μ M in 
the presence of GABA and carvacrol, which is highly 
significant compared both to the control and the EC50 
of bephenium obtained in the presence of GABA 
(Table 1). Something different was obtained with 
the maximum contractile effect of bephenium (Rmax), 
because it did not change in the presence of GABA. 
However, the combination of GABA and carvacrol 
significantly reduced the Rmax value from 2.2 to 0.89 g 
(Table 2).
The EC50 of morantel did not change significantly 
in the presence of GABA and in the presence of 
a combination of GABA and carvacrol (morantel 
EC50 = 3.72, 5.69, and 7.94 nM) (Table 1). Moreover 
GABA 3 μ M did not change the Rmax of morantel either, 
but the combination of GABA and carvacrol significantly 
reduced the value of the maximal contractile effect 
(Table 2). Figure 3 shows a representative recording of 
A. suum muscle strip contractions caused by morantel 
(Fig. 3A) and sigmoid concentration dose–responses 
plot (Fig. 3B).
The applied concentration of GABA (3 μ M) did not 
cause relaxation of the tested muscle strips.
Discussion
We believe that the concept of simultaneous use of 
compounds with multiple sites of antiparasitic action 
is able to prevent the development of resistance in 
parasites. We have shown in previous studies that 
carvacrol is most likely to act as a non-competitive 
inhibitor of nAChRs of nematodes (Marjanović et al., 
2020; Trailović et al., 2015). It is known that one of 
the mechanisms for the development of resistance 
involves a change in the receptor to which the drug 
binds (Abongwa et al., 2017). For example, it is 
known that pyrantel resistance is associated with a 
modification of the target nicotinic receptor properties 
(Robertson et al., 2000). Whether this can also refer 
to the change of only certain subtypes of the nicotinic 
receptor has not been clarified.
Pyrantel is an anthelmintic from the tetrahydro-
pyrimidine group. It is used in veterinary and human 
medicine against gastrointestinal nematodes. Pyrantel 
is a fairly selective agonist of nAChRs. It produces 
depolarization and contraction of the nematode body 
muscle which causes spastic paralysis. Pyrantel is a 
relatively potent agonist (EC50 ~ 10 µM) on leva misole 
receptor subtypes (L-subtype) of nematode nAChRs. 
Our results are in accordance with the presented 
data. In our study, the contractile EC50 of pyrantel for 
A. suum muscle flaps was 8.44 μ M, and it increased 
more than threefold in the presence of GABA, without 
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Table 1. EC50 (±S.E.) values of pyrantel, bephenium, and morantel in the presence of 
GABA and carvacrol.
Control GABA 3 μ M GABA 3 μ M + Carvacrol 100 μ M Wash
Pyrantel (nM) 8.44 ± 1.56 28.11 ± 1.61**** 44.62 ± 2.70****++++ 20.51 ± 2.34***oooo
Bephenium (μ M) 0.62 ± 0.11 0.96 ± 0.21 1.40 ± 0.12*** 1.32 ± 0.09**
Morantel (nM) 3.72 ± 1.73 5.69 ± 2.12 7.94 ± 2.35 15.81 ± 4.03*+
Notes: *Statistically significant difference compared to control (***p < 0.0001; ***p = 0.0007; ***p = 0.0008; 
**p = 0.0032; *p = 0.0108); +statistically significant difference compared to GABA 3 μ M (++++p < 0.0001; +p = 0.0429); 
ostatistically significant difference compared to GABA 3 μ M + Carvacrol 100 μ M (oooop < 0.0001).
Figure 1: A Original recording of isometric contractions of A. suum muscle flap induced by 
increasing concentrations of pyrantel and the effect of GABA (3 μ M) and Carvacrol (100 μ M) on 
those contractions; B the concentration-response plot for pyrantel control (n = 6, blue), in the 
presence of GABA 3 μ M (n = 6, green), in the presence of GABA and Carvacrol 100 μ M (n = 6, 
red) and after washing (n = 6, dashed black) (mean ± S.E.).





2.0 Pyrantel - Control
GABA 3 µM












































Figure 2: A Original recording of isometric contractions of A. suum muscle flap induced by 
increasing concentrations of bephenium and the effect of GABA (3 μ M) and Carvacrol (100 μ M) 
on those contractions; B the concentration-response plot for bephenium control (n = 6, blue), in 
the presence of GABA 3 μ M (n = 6, green), in the presence of GABA and Carvacrol 100 μ M (n = 6, 
red) and after washing (n = 6, dashed black) (mean ± S.E.).
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Table 2. Rmax (g ± S.E.) values of pyrantel, bephenium, and morantel in the presence of 
GABA and carvacrol.
Control GABA 3 μ M GABA 3 μ M + Carvacrol 100 μ M Wash
Pyrantel 1.52 ± 0.12 1.38 ± 0.20 0.47 ± 0.15****+++ 0.77 ± 0.17**+
Bephenium 2.20 ± 0.30 2.18 ± 0.34 0.89 ± 0.22**++ 1.15 ± 0.23*+
Morantel 1.16 ± 0.07 0.99 ± 0.11 0.39 ± 0.11****+++ 0.59 ± 0.15***o
Notes: *Statistically significant difference compared to control (****p < 0.0001; ***p = 0.0007; **p = 0.0448; 
**p = 0.0062; *p = 0.0475); +statistically significant difference compared to GABA 3 μ M (+++p = 0.0008; +p = 0.0429; 
++p = 0.0072; +p = 0.0475; +++p = 0.0003); ostatistically significant difference compared to GABA 3 μ M + Carvacrol 
100 μ M (op = 0.0298).
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altering the Rmax. Such an inhibition is manifested by 
competitive antagonists, but GABA certainly is not 
a competitive antagonist of nAChRs. We previously 
obtained a similar result with ACh and hypothesized 
that this phenomenon occurs as a consequence of 
the binding of GABA, in low concentrations, to the 
GABA receptor in the synapses between inhibitory 
interneurons and motoneurons (synaptic effect). 
This process immediately activates the competitive 
antagonistic excitatory mechanism through excitatory 
interneurons (Trailović et al., 2015). On the other 
hand, this study shows that the addition of carvacrol 
had a non-competitive antagonistic effect because 
the Rmax was reduced by more than three times. We 
hypothesize that carvacrol cannot bind presynaptically 
but rather postsynaptically to a different site on nAChR 
than pyrantel, resulting in non-competitive antagonism.
Bephenium is an anthelmintic compound used 
against human and dog hookworms and gastro-
intestinal parasitic nematodes in sheep (Burrows, 
1958). Bephenium activates the B-subtype of the 
nAChRs of nematodes (Martin and Robertson, 
2007), but there is no more detailed information on 
the mechanism of action. In our study, GABA did 
not alter the EC50 of bephenium, nor did it affect the 
maximal contractile effect (Rmax). Furthermore, the 
addition of carvacrol led to a significant increase in 
bephenium EC50 but also a decreased the Rmax. This 

















































Figure 3: A Original recording of isometric contractions of A. suum muscle flap induced by 
increasing concentrations of morantel and the effect of GABA (3 μ M) and carvacrol (100 μ M) on 
those contractions; B the concentration-response plot for morantel control (n = 6, blue), in the 
presence of GABA 3 μ M (n = 6, green), in the presence of GABA and carvacrol 100 μ M (n = 6, red) 
and after washing (n = 6, dashed black) (mean ± S.E.).
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is obviously mostly non-competitive antagonism and 
can be explained by the fact that carvacrol binds to 
a different site on the receptor relative to the binding 
site of bephenium, and that the B-subtype of nAChRs 
are predominantly located postsynaptically.
The results obtained with morantel are especially 
interesting. Morantel also belongs to tetrahydro-
pyrimidines, but it is still not clear which subtype of 
nAChRs it predominantly prefers. The incubation 
of the muscle strips with GABA did not significantly 
change the EC50 of morantel, nor the Rmax value. 
There was no significant change in EC50 of morantel 
even after the incubation with the combination of 
GABA + carvacrol, but the Rmax was significantly 
reduced. Similar to bephenium, we can state that 
the inhibitory effect of GABA is almost absent, while 
the combination of GABA and carvacrol exhibits 
mostly non-competitive antagonism. As before, we 
could assume that the receptors to which morantel 
binds are predominantly localized postsynaptically, 
which causes the absence of activation of inhibitory 
interneurons, and consequent competitive response. 
Courtot et al. (2015) reported that ACR-26 and ACR-
27, the nAChRs subunits from Parascaris equorum 
expressed in Xenopus oocyte, are able to form a 
functional nAChR highly sensitive to pyrantel and 
morantel.
In our previous study (Trailović et al., 2015), 
GABA 3 μ M shifted the acetylcholine EC50 to the 
right, producing a dose-ratio (EC50control/EC50GABA) 
of 2.39, while the Rmax was reduced by 30%. Now, 
after the incubation with 3 μ M of GABA the dose 
ratios were 3.33 for pyrantel, 1.54 for bephenium, 
and 1.60 for morantel. On the other hand, Rmax for 
pyrantel, bephenium, and morantel was reduced 
by 9, 0.1, and 14.6%, respectively. It is obvious that 
GABA most effectively inhibits the effect of pyrantel 
and that the majority of this effect is competitive. We 
assume that this is the result of the synaptic effect 
in the synapses between inhibitory interneurons 
and motoneurons. However, when GABA was 
combined with carvacrol the dose-ratio (EC50control/
EC50GABA + carvacrol) was 6.93, 2.25, and 2.13 for pyrantel, 
bephenium, and morantel, respectively, while Rmax 
decreased by 70, 60, and 65%, respectively. Their 
effect is more dominantly non-competitive, but also 
indicates that the combined use of GABA receptor 
agonists and nicotinic receptor antagonists can 
effectively inhibit the neuromuscular system of 
nematodes, even when one of the nicotinic receptor 
subtypes is dysfunctional due to the development 
of resistance. This is useful information for the 
formulation of commercial drugs that could prevent 
and overcome resistance.
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